Your session is about to expire
← Back to Search
LB-102, 75 mg QD for Schizophrenia
Study Summary
This trial is being conducted to assess the effectiveness and safety of a drug called LB-102 in adult patients with schizophrenia experiencing worsening symptoms. The study will compare the effects of LB-102 to a placebo
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are participants currently being actively enrolled in this research study?
"Indeed, the current information on clinicaltrials.gov confirms that this trial is actively seeking participants. The initial posting of the study took place on December 4th, 2023 and it was most recently updated on December 12th, 2023. A total of 350 patients are being sought across a network of 25 different sites."
Does this medical study enroll individuals who are aged 55 years or older?
"This clinical investigation is seeking individuals who have reached the age of majority but are not older than 55 years."
At how many different sites is this clinical trial currently being conducted?
"This study is currently enrolling a total of 25 patients. Notable enrollment sites include Pillar Clinical Research in Bentonville, CelExel Clinical Innovations in Bellflower, and Synexus in Cerritos. Additionally, there are 25 other locations where participants can be enrolled."
Has the Food and Drug Administration granted approval for the daily administration of LB-102 at a dosage strength of 50 milligrams?
"Based on our assessment, LB-102 at a dosage of 50 mg once daily is estimated to have a safety rating of 2. This evaluation is based on the fact that this trial belongs to Phase 2, indicating some existing data supporting its safety but lacking evidence for efficacy."
What is the current number of individuals being admitted into this clinical investigation?
"To successfully conduct this study, a total of 350 eligible participants who meet the inclusion criteria are needed. LB Pharmaceuticals Inc., the sponsor of the trial, will oversee operations from various sites including Pillar Clinical Research in Bentonville, California and CelExel Clinical Innovations in Bellflower, Florida."
Do I meet the necessary criteria to participate in this clinical investigation?
"In order to meet the eligibility criteria for this clinical trial, participants must have a diagnosis of schizophrenia and fall within the age range of 18 to 55 years. The study has capacity to enroll up to 350 individuals."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger